Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Request a free trial

No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: gadobutrol

« Back to Dashboard
Gadobutrol is the generic ingredient in one branded drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has twenty-four patent family members in sixteen countries.

There is one drug master file entry for gadobutrol. One supplier is listed for this compound.

Summary for Generic Name: gadobutrol

Tradenames:1
Patents:1
Applicants:1
NDAs:1
Drug Master File Entries: see list1
Suppliers / Packaging: see list10
Formulation / Manufacturing:see details

Pharmacology for Ingredient: gadobutrol

Clinical Trials for: gadobutrol

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
Status: Completed Condition: Brain Diseases; Spinal Cord Diseases

Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging
Status: Completed Condition: Diagnostic Imaging; Central Nervous System Diseases

Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging
Status: Completed Condition: Central Nervous System Diseases

Myocardial Perfusion MRI
Status: Completed Condition: Myocardial Perfusion Imaging; Magnetic Resonance Imaging

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
Status: Completed Condition: Breast Cancer

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI
Status: Completed Condition: Breast Cancer; Diagnostic Imaging

Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)
Status: Completed Condition: Magnetic Resonance Imaging

A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children
Status: Completed Condition: Magnetic Resonance Imaging

Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Status: Recruiting Condition: Coronary Artery Disease

Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Status: Active, not recruiting Condition: Coronary Artery Disease

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare
GADAVIST
gadobutrol
SOLUTION;INTRAVENOUS201277-005Mar 14, 2011RXYes<disabled><disabled>
Bayer Hlthcare
GADAVIST
gadobutrol
SOLUTION;INTRAVENOUS201277-004Mar 14, 2011RXYes<disabled><disabled>
Bayer Hlthcare
GADAVIST
gadobutrol
SOLUTION;INTRAVENOUS201277-003Mar 14, 2011RXYes5,980,864<disabled>YY<disabled>
Bayer Hlthcare
GADAVIST
gadobutrol
SOLUTION;INTRAVENOUS201277-003Mar 14, 2011RXYes<disabled><disabled>
Bayer Hlthcare
GADAVIST
gadobutrol
SOLUTION;INTRAVENOUS201277-001Mar 14, 2011RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: gadobutrol

Country Document Number Publication Date
Finland911330Sep 20, 1991
Spain2074219Sep 01, 1995
Germany10075007Jun 12, 2003
Israel97592Jun 21, 1992
Norway179610Nov 13, 1996
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc